SAVA
vs
S&P 500
SAVA
S&P 500
Over the past 12 months, SAVA has underperformed S&P 500, delivering a return of -17% compared to the S&P 500's +12% growth.
Stocks Performance
SAVA vs S&P 500
Performance Gap
SAVA vs S&P 500
Performance By Year
SAVA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cassava Sciences Inc
Glance View
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 24 full-time employees. The company went IPO on 2000-07-14. The firm is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer's brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. The company is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimer's disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.
